Celldex Therapeutics, Inc.

Contributing Author

Recent Articles by Celldex Therapeutics, Inc.

Apr-01	Celldex Announces Pricing of $300 Million Public Offering of Common Stock CLDX GlobeNewswire
Apr-01	Celldex Announces Proposed Public Offering of Common Stock CLDX GlobeNewswire
Mar-27	Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 CLDX GlobeNewswire
Mar-01	Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 CLDX GlobeNewswire
Feb-27	Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 CLDX GlobeNewswire
Feb-25	Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update CLDX +24.07% GlobeNewswire
Feb-25	Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria CLDX +24.07% GlobeNewswire
Feb-23	Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile CLDX +5.65% GlobeNewswire
Feb-09	Celldex to Present at Upcoming Investor Conferences CLDX GlobeNewswire
Dec-09	Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism CLDX -5.74% GlobeNewswire
Nov-10	Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update CLDX +7.50% CLDX GlobeNewswire
Nov-10	Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer CLDX GlobeNewswire
Nov-07	Celldex to Present at Upcoming Investor Conferences CLDX GlobeNewswire
Nov-06	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study CLDX GlobeNewswire
Nov-06	Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 CLDX GlobeNewswire
Oct-30	Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition CLDX GlobeNewswire
Sep-17	Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 CLDX GlobeNewswire
Sep-09	Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference CLDX GlobeNewswire
Aug-19	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) CLDX -13.03% CLDX GlobeNewswire
Aug-07	Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update CLDX GlobeNewswire
Jun-14	Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 CLDX GlobeNewswire
Jun-12	Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 CLDX GlobeNewswire
Jun-10	Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress CLDX GlobeNewswire
Jun-06	Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors CLDX +9.32% GlobeNewswire
May-08	Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update CLDX -6.10% CLDX GlobeNewswire
May-05	Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease CLDX -9.31% CLDX GlobeNewswire

Celldex Therapeutics, Inc.

Recent Articles by Celldex Therapeutics, Inc.

Upgrade your Finviz experience